Biotherapeutics News for January 2010

Amarin corporation announces first patients enrolled in two Phase III clinical trials assessing AMR101 for the treatment of cardiovascular disease Amarin corporation announces first patients enrolled in two Phase III clinical trials assessing AMR101 for the treatment of cardiovascular disease

Lowering triglyceride levels for at-risk patients: first patients enrolled in MARINE and ANCHOR Phase III clinical trials for AMR101.
12 January, 2010